462 results on '"Lussier, Firoza Z."'
Search Results
52. Sex-specific modulation of amyloid-β on tau phosphorylation underlies faster tangle accumulation in females.
53. Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals.
54. Interactive rather than independent effect of APOE and sex potentiates tau deposition in women
55. Plasma p‐tau231 and p‐tau217 inform on tau tangles aggregation in cognitively impaired individuals
56. APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles
57. Amyloid beta plaque accumulation with longitudinal [18F]AZD4694 PET
58. The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework
59. Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer’s disease
60. Plasma and CSF concentrations of N‐terminal tau fragments associate with in vivo neurofibrillary tangle burden
61. Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.
62. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
63. APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles
64. Blood‐brain barrier integrity impacts the use of plasma amyloid‐β as a proxy of brain amyloid‐β pathology
65. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography
66. Medial temporal tau predicts memory decline in cognitively unimpaired elderly
67. Tau phosphorylation is more closely associated with amyloid‐β plaques than with tau neurofibrillary tangles
68. Brain TSPO expression is associated with plasma pTau181 & pTau231 across the AD spectrum
69. Verbal recognition declines in later Braak Stages compared to verbal delayed recall
70. Comparison of plasma amyloid, tau, and astrocyte biomarkers to identify AD pathophysiology
71. pTau heterogeneity as a measure for disease severity in incipient Alzheimer's disease
72. TRIAD multi‐dimensional biobank for biomarker discovery
73. Role of astrogliosis in the relationship between cerebrovascular burden and Alzheimer’s disease pathology
74. Association between tau uptake and verbal fluency converge in language centers
75. Neuroinflammation is associated with the rising of early Alzheimer’s disease pathology in amyloid‐negative elderly
76. Amyloid and tau pathologies associate with distinct aspects of the inflammatory cascade
77. Impact of meningeal and age‐related off‐target binding on longitudinal [18F]MK6240 quantification
78. Impact of meningeal and age‐related off‐target binding on longitudinal [ 18 F]MK6240 quantification.
79. Biomarker modelling of Alzheimer's disease using in vivo Braak staging
80. Situating tau pathology and neuroinflammation along the principal gradients of brain organisation in Alzheimer’s disease
81. Longitudinal changes in plasma p‐tau181 as a surrogate variable to populational interventions
82. Apolipoprotein E ε4 associates with microglial activation in early Braak regions independently of amyloid‐β and tau
83. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions
84. Additional file 1 of CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals
85. Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer’s disease
86. Late‐life hypertension acts together with amyloid‐β pathology to promote early cognitive decline.
87. APOEε4 carriership associates with microglial activation independently of Aβ plaques and tau tangles
88. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [18F]MK6240 Tau PET in Target Regions.
89. Comparing tau status determined via plasma pTau181, pTau231 and [18F]MK6240 tau-PET
90. Associations between neutrophils and amyloid deposition in the Alzheimer’s disease spectrum
91. Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe
92. Discrepancy between plasma pTau181 and tau‐PET statuses
93. Plasma p‐Tau181 and p‐Tau231 offer complementary information to identify Alzheimer's disease pathophysiology
94. Adapting to the COVID‐19 pandemic in cohort studies: Validation of online assessments of cognition and neuropsychiatric symptoms in an aging population
95. Tau accumulation using [18F]MK6240 PET is associated with increase in executive dysfunction in prodromal AD
96. Effect of temporal meta‐ROI and Braak1&2 ROI on the dissociation between plasma pTau181 and PET statuses
97. Verbal fluency associated with tau accumulation and not amyloid deposition in the Alzheimer’s disease spectrum
98. Cognitive health mediates the effect of hippocampal volume on COVID‐19‒related knowledge or anxiety change during the COVID‐19 pandemic
99. Microglial activation and tau propagate jointly across Braak stages
100. COVID‐19 pandemic: Quantifying the effects of the first lockdown on behavioral and cognitive measures using TASIC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.